103 results
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
25 Mar 24
Results of Operations and Financial Condition
7:03am
, and commercial milestones; tiered royalties of up to low 20’s on net sales; and reimbursement of KIO-301 research and development expenses.
Completed … million and the Company believes this will fund operations through 2026.
In 2023, research and development expenses were $4.0 million, net of $1.7 million
8-K
EX-99.1
KPRX
Kiora Pharmaceuticals Inc
12 Feb 24
Regulation FD Disclosure
5:23pm
to reimburse Kiora for KIO-301 Research & Development Development Costs for Ph3 Thea to cover 100% Upfront Payment $16M Development & Commercial
8-K
EX-99.1
73r4si uk8
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
EX-99.1
9tjnlpom28a wwh1eh0
9 Nov 23
Results of Operations and Financial Condition
7:01am
8-K
EX-99.1
mx3j7f rh5uap4vxf
8 Aug 23
Kiora Pharmaceuticals Announces Q2 2023 Earnings and Business Update, Highlighting Pipeline Updates and Clinical Development Progress
7:14am
8-K
EX-99.1
eituh46 eh92gwpg
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
gzd4cjt938vhw2hnnjl
1 Aug 23
Biotech Leader Carmine Stengone Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EX-10.1
k8x1dcm
15 Jun 23
Kiora Pharmaceuticals and Sentrx Animal Care Amend Existing Manufacturing Licensing Agreement for KIO-201
4:59pm
424B1
9q9w28
2 Jun 23
Prospectus with pricing info
5:08pm
8-K
EX-99.1
ty6b8j322u
9 May 23
Kiora Pharmaceuticals Reports First Quarter Results; Positive Clinical Data Driving Significant Progress Advancing Pipeline of Eye Disease Treatments
7:02am